Educating Teens About Vaccines

Journal of Pediatric Health Care

Volumn 20, Issue 5, 2006, Pages 342-349

  Hernandez, Georgianna ^a   Nestor, Courtney ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; MEASLES MUMPS RUBELLA VACCINE; MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE; MENINGOCOCCUS VACCINE; PAPILLOMA VIRUS VACCINE; VACCINE; VIRUS VACCINE;

ADOLESCENT; ARTICLE; CHILD HEALTH CARE; DRUG INFORMATION; HEALTH EDUCATION; HUMAN; IMMUNIZATION; METHODOLOGY; NURSE ATTITUDE; NURSING; ORGANIZATION AND MANAGEMENT; PEDIATRIC NURSING; PUBLIC HEALTH SERVICE; UNITED STATES; VACCINATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHICKENPOX VACCINE; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG INFORMATION SERVICES; HEALTH EDUCATION; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MEASLES-MUMPS-RUBELLA VACCINE; MENINGOCOCCAL VACCINES; NURSE'S ROLE; PAPILLOMAVIRUS VACCINES; PEDIATRIC NURSING; UNITED STATES; VACCINATION; VACCINES, COMBINED; VIRAL VACCINES;

EID: 33748141970     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2006.07.002     Document Type: Article

References (31)

1. ACOG Committee on Adolescent Health Care. Committee opinion: Meningococcal vaccination for adolescents. Obstetrics & Gynecology 106 (2005) 667-669
2. American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 116 (2005) 496-505
3. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: Recommended childhood and adolescent immunization schedule-United States, 2006. Pediatrics 117 (2006) 239-240
4. Arvin A., and Greenberg H. New viral vaccines. Virology 344 (2005) 240-249
5. Bonnez W. Immunization against genital human papillomavirus. The Pediatric Infectious Disease Journal 24 (2005) 1005-1006
6. Centers for Disease Control and Prevention. National, state and urban area vaccination coverage among children aged 19-35 months: United States, 2003. MMWR: Morbidity and Mortality Weekly Review 53 (2004) 658-661
7. Centers for Disease Control and Prevention. Notice to readers: Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR: Morbidity and Mortality Weekly Review 54 (2005) 1212-1215
8. Centers for Disease Control and Prevention. Vaccines for children program: Vaccines to prevent measles, mumps, rubella, and varicella (2005), Advisory Committee on Immunization Practices, Atlanta, GA. http://www.cdc.gov Retrieved May 23, 2006, from the Centers for Disease Control and Prevention Web site: www.cdc.gov
9. Centers for Disease Control and Prevention. Genital HPV infection fact sheet (2006), CDC National Prevention Information Network, Atlanta, GA. http://www.cdc.gov Retrieved May 23, 2006, from the Centers for Disease Control and Prevention Web site: www.cdc.gov
10. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule--United States, 2006. MMWR Weekly 54 52 (2006) Q1-Q4. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5451-Immunizational.htm?s_cid=mm5 Retrieved March 4, 2006, from the Centers for Disease Control and Prevention Web site: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5451-Immunizational.htm?s_cid=mm5
11. Cohen A.C., Broder K.R., and Pickering L.K. Immunizations in the United States: A rite of passage. Pediatric Clinics of North America 52 (2005) 669-693
12. Committee of Infectious Diseases. Policy statement: Prevention of pertussis among adolescents: Recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117 (2006) 965-978
13. Dempsey A., Zimet G., Davis R., and Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: A randomized intervention study of written information about HPV. Pediatrics 117 (2006) 1486-1493
14. Food and Drug Administration. FDA licenses quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil) for the prevention of cervical cancer and other diseases in females caused by human papillomavirus. FDA Center for Drug Evaluation and Research (2006). http://www.fda.gov/cder/Offices/OODP/gardasil.htm Retrieved August 2, 2006, from the Food and Drug Administration Website: www.fda.gov/cder/Offices/OODP/gardasil.htm
15. Food and Drug Administration. Product approval information: Licensing action. FDA Center for Drug Evaluation and Research (2006). http://www.fda.gov/cder/label/hpvmer060806LB.htm Retrieved August 2, 2006, from the Food and Drug Administration Website: www.fda.gov/cder/label/hpvmer060806LB.htm
16. Guinto-Oampo H., McNeil B.K., and Aronoff S.C. Pertussis (2006). http://www.emedicine.com/ped/topic1778.htm Retrieved May 27, 2006, from the eMedicine Web site: http://www.emedicine.com/ped/topic1778.htm
17. Harper D., Franco E., Wheeler C., Moscicki A., Romanowski B., Roteli-Martins C., Teixeira J., Blatter M.M., Korn A.P., Quint W., Dubin G., and GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 364 (2004) 1757-1765
18. Harper D., Franco E., Wheeler C., Moscicki A., Romanowski B., Roteli-Martins C., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G., and HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 367 (2006) 1247-1255
19. Humiston S.G., and Rosenthal S.L. Challenges to vaccinating adolescents-Vaccine implementation issues. The Pediatric Infectious Disease Journal 24 Suppl. (2005) S134-S140
20. Knuf M., Habermehl P., Zepp F., Mannhardt W., Kuttnig M., Muttonen P., Prieler A., Maurer H., Bisanz H., Tornieporth N., Descamps D., and Willems P. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. The Pediatric Infectious Disease Journal 25 (2006) 12-18
21. Morantz C. Practice guidelines: ACIP updates recommendations for prevention of hepatitis B virus transmission. American Family Physician 73 (2006) 1839-1847
22. Nguyen H., Jumaan A., and Seward J. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. New England Journal of Medicine 352 (2005) 450-458
23. Nolan T., McIntyre P., Roberton D., and Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 21 (2002) 281-289
24. Olshen E., Woods E., Austin A., Luskin M., and Bauchner H. Parental acceptance of the human papillomavirus vaccine. Journal of Adolescent Health 37 (2005) 248-251
25. Shinefield H., Black S., Williams W.R., Marchant C., Reisinger K., Stewart T., Meissner H.C., Guerrero J., Klopfer S.O., Xu J., Schodel F., Kuter B.J., and Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella, and varicella vaccine in healthy children. The Pediatric Infectious Disease Journal 24 (2005) 670-675
26. Shinefield H., Black S., Digilio L., Reisinger K., Blatter M., Gress J.O., Brown M.L., Eves K.A., Klopfer S.O., Schodel F., and Kuter B.J. Evaluation of a quadrivalent measles, mumps, rubella, and varicella vaccine in healthy children. The Pediatric Infectious Disease Journal 24 (2005) 665-669
27. Shinefield H., Black S., Staehle B., Matthews H., Adelman T., and Ensor K. Vaccination with measles, mumps, and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody, and duration of protection against varicella in healthy children. The Pediatric Infectious Disease Journal 21 (2002) 555-561
28. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6,11,16,and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 6 (2005) 271-278
29. Williamson A., Passmore J., and Rybicki A. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Clinical Obstetrics & Gynecology 19 (2005) 531-544
30. Yu A.S., Cheung R.C., and Keefe E.B. Hepatitis B vaccines. Infectious Disease Clinics of North America 20 (2006) 27-45
31. Zimet G. Improving adolescent health: focus on HPV vaccine acceptance. Journal of Adolescent Health, 37 (2005) S17-S23